ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biobased chemicals firm Amyris is launching a drug discovery and production business based on its technology for designing microbes for biochemical synthesis. Amyris says the business is an outgrowth of its successful production of the malaria drug precursor artemisinic acid and its experience scaling up biobased chemicals. Customers will receive gene-editing tools, high-throughput screening technology, and industrial-scale fermentation infrastructure. The company says its processes are ideal for making compounds for which a natural source is scarce or chemical synthesis is not cost-effective.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter